Bicara Therapeutics Inc (BCAX) Price

Bicara Therapeutics, Inc. is a clinical-stage biotechnology company developing first-in-class biologics engineered to combine the precision of well-validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company is headquartered in Boston, Massachusetts, and currently employs 55 full-time employees. It went public on September 13, 2024. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets: a monoclonal antibody directed against epidermal growth factor receptor (EGFR) and a domain that binds to human transforming growth factor beta (TGF-β). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation pathways and the immunosuppressive TGF-β signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed for the treatment of head and neck squamous cell carcinoma, where there remains a significant unmet medical need. The company's platform is designed to facilitate the development of bifunctional therapies that precisely target tumors and deliver tumor-modulating payloads directly to the tumor site.